Provided by Tiger Fintech (Singapore) Pte. Ltd.

Atara Biotherapeutics

7.67
+0.42005.79%
Volume:138.11K
Turnover:1.11M
Market Cap:44.94M
PE:-0.67
High:8.65
Open:8.00
Low:7.43
Close:7.25
Loading ...

Atara Biotherapeutics Shares Resume Trading, Down 45% Premarket After US FDA Declines to Approve Co's Cancer Therapy

THOMSON REUTERS
·
16 Jan

BRIEF-Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Reuters
·
16 Jan

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Reuters
·
16 Jan

Atara Biotherapeutics: Intends to Suspend All CAR-T Activities, Significantly Cut Expenses IF Resolution Not Reached for Funding for Programs in Q1

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Inc: Crl Did Not Identify Deficiencies Related to Clinical Efficacy or Safety Data in Bla

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Inc: Engaged Advisor to Support Exploration of All Strategic Options

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Provides Regulatory and Business Update on Ebvallotm (Tabelecleucel)

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics: Got Into Non-Binding Term Sheet With Redmile Group to Provide up to $15 Mln in Funding

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Inc: Received FDA Complete Response Letter (Crl) Solely Related to Inspection Findings at Third-Party Manufacturer

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Shares Halted for News Pending Premarket

THOMSON REUTERS
·
16 Jan

Here's Why You Should Consider Buying Atara Biotherapeutics Stock

Zacks
·
08 Jan

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) high institutional ownership speaks for itself as stock continues to impress, up 27% over last week

Simply Wall St.
·
08 Jan

Bionano Announces Publication Showing that OGM Identifies Variant that Indicates Use of Proven Therapy in Acute Promyelocytic Leukemia

GlobeNewswire
·
07 Jan

Atara Biotherapeutics (ATRA) Upgraded to Buy: Here's Why

Zacks
·
03 Jan

Atara Biotherapeutics Initiated at Buy by Rodman & Renshaw

Dow Jones
·
20 Dec 2024

Rodman & Renshaw Initiates Coverage on Atara Biotherapeutics With Buy Rating, $25 Price Target

MT Newswires Live
·
20 Dec 2024

Atara Biotherapeutics initiated with a Buy at Rodman & Renshaw

TIPRANKS
·
20 Dec 2024

Kyverna Therapeutics Picks Former Atara Bio, Kite Executives for Leadership Roles

MT Newswires Live
·
14 Dec 2024

Atara Biotherapeutics to Participate at the 7th Annual Evercore ISI HealthCONx Conference

Business Wire
·
28 Nov 2024

Atara Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.
·
15 Nov 2024